Phase I, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination With Pembrolizumab in Patients With KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma
Summary
This phase I study will determine the safety and tolerability and establish a preliminary recommended phase II dose of V941(mRNA-5671/V941) as a monotherapy and in combination with pembrolizumab infusion.
General Information
NCT#: NCT03948763
Study ID: V941-001
Trial Phase: Phase I
Trial Sponsor: Merck Sharp & Dohme Corp.
Therapies Used in This Trial: Pembrolizumab, mRNA-5671/V941